Laura Hesemann, MD
Pediatric Nephrology · Columbia, MONPI 1790972586
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,810 of the $8,213 with a category attached, or 95.1%. Amgen accounts for 92.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $2,325 and has fallen 97.8% since, to $52 in 2025.
Across 23 payments — averaging $357.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$8K
- AstraZeneca$250
- Coopervision Inc.$84
- Baxter Healthcare$66
- Novartis$52
- Akebia Therapeutics Inc$46
- plus $155 from 7 others
What the payments were for
- Consulting fees$511%
- Speaking & faculty fees$7,81095%
- Food & beverage$3504%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $7,560 |
| AstraZeneca | 1 | $250 |
| Coopervision Inc. | 1 | $84 |
| Baxter Healthcare | 2 | $66 |
| Novartis | 2 | $52 |
| Akebia Therapeutics Inc | 4 | $46 |
| Sanofi | 2 | $45 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $25 |
| Mozarc Medical US LLC | 1 | $23 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Vifor Pharma, Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCYSBI$7,560
How this compares
$8,213 in reported general payments places this provider in the 80th percentile of 26 pediatric nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Calcitriol | 20 | $501 |
| Hydrochlorothiazide | 12 | $36 |
Paid to pharmacies, not to this prescriber.
Other pediatric nephrology in Columbia
- Jeffrey SteinColumbia$104
- Bradley WaradyKansas City$61K
- Tarak SrivastavaKansas City$28K
- Uri AlonKansas City$22K
- Judith VansickleKansas City$18K
- Laurel WilligKansas City$17K
- Raja Sekhar DandamudiSaint Louis$3K
- Vimal ChadhaKansas City$2K
- Keith HruskaSaint Louis$2K
- Eileen CicciaSaint Louis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.